16 Sep 2026 Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial Investors | Therapeutics
14 Sep 2026 Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee Investors
08 Jul 2026 Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors Investors